AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (5.7 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Publishing Language: Chinese | Open Access

Zinc finger protein ZNF322 promotes malignant progression of glioblastoma

Yan Shang, Yi Li, Chao Lu ( )
Department of Pediatrics, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
Show Author Information

Abstract

Objective

To investigate the expression characteristics, clinical prognostic significance, immune microenvironment correlation of zinc finger protein ZNF322 in glioblastoma (GBM), as well as its effect on the biological functions of GBM cells.

Methods

The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases were used to analyze the expression differences of ZNF322 in glioma and GBM tissues and its relationship with patient prognosis. Kaplan-Meier survival curves, univariate and multivariate Cox regression analyses were performed to evaluate the prognostic value of ZNF322. Single-cell transcriptome data (GSE162631) were analyzed to determine the distribution characteristics of ZNF322 in malignant cell subpopulations of GBM. The CIBERSORTx algorithm was used to assess the correlation between ZNF322 expression and immune cell infiltration. ZNF322 knockdown and overexpression models were established in U87MG cells. CCK-8 assay, wound healing assay, and flow cytometry were used to detect cell proliferation, migration, and cell cycle changes, respectively.

Results

The expression level of ZNF322 in glioma and GBM tissues was significantly higher than that in normal brain tissue (P < 0.05), and its high expression was significantly associated with adverse clinical-pathological features such as WHO grading, mutational status of isocitrate dehydrogenase, and histological type (all P < 0.01). Univariate and multivariate Cox regression analyses demonstrated that high ZNF322 expression was an independent prognostic risk factor for GBM patients (HR=1.51, 95%CI: 1.15-1.99, P=0.003). Kaplan-Meier survival curves confirmed that patients with high ZNF322 expression had significantly shorter overall survival compared to those with low expression (P < 0.01). Single-cell transcriptome analysis revealed that ZNF322 was predominantly enriched in malignant cell subpopulations resembling oligodendrocytes-like and oligodendrocyte progenitors-like. Immunohistochemical infiltration analysis showed that ZNF322 exhibited negative correlations with immune cells such as natural killer cells and dendritic cells, suggesting its involvement in the remodeling of the GBM immune microenvironment. Functional enrichment analysis indicated that upregulated ZNF322 was significantly enriched in pathways related to chromosome segregation and cell cycle, whereas downregulated ZNF322 was enriched in pathways involving synaptic signaling regulation and neurotransmitter transport. In vitro, ZNF322 knockdown inhibited U87MG cell proliferation and migration and induced G0/G1-phase arrest; overexpression produced the opposite effects and increased the proportion of cells in G2/M phase.

Conclusion

ZNF322 is highly expressed in GBM and is closely associated with poor patient prognosis. It may participate in the malignant progression of GBM by regulating the cell cycle and immune microenvironment. ZNF322 has the potential to serve as a prognostic biomarker and a molecular therapeutic target for GBM.

CLC number: R739.41 Document code: A Article ID: 1007-4368(2026)11-1619-12

References

【1】
【1】
 
 
Journal of Nanjing Medical University (Natural Sciences)
Pages 1619-1630

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Shang Y, Li Y, Lu C. Zinc finger protein ZNF322 promotes malignant progression of glioblastoma. Journal of Nanjing Medical University (Natural Sciences), 2026, 46(11): 1619-1630. https://doi.org/10.7655/NYDXBNSN260369

4

Views

0

Downloads

0

Crossref

Received: 25 March 2026
Revised: 28 June 2026
Accepted: 11 July 2026
Published: 15 November 2026
© 2026 Editorial Board of Journal of Nanjing Medical University(Natural Sciences)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).